Amrutanjan Health Care Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹135 Cr +14.4% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
AH

Amrutanjan Health Care Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Amrutanjan Health Care Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹94Cr
+11.9% YoY
−30.4% QoQ
Net profit
₹8Cr
+60% YoY
−46.7% QoQ
Margin
9%
+4.8 pp YoY
−4 pp QoQ

Based on Amrutanjan Health Care Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹510
Market cap₹1.4K Cr
P/E23.0

The short version

Overall Financial Performance Q1 FY26 vs Q1 FY25:. EBITDA/profit before tax (PBT) for Q1 FY26: Rs. 11.29 Cr, up 77.80% YoY (from Rs. 6.35 Cr in Q1 FY25) [Page 16].

From Amrutanjan Health Care Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Overall Financial Performance Q1 FY26 vs Q1 FY25:
  • Net Sales: Rs. 94.05 Cr, up 12.31% from Rs. 83.74 Cr
  • Gross Sales: Rs. 107.19 Cr, up 14.58% from Rs. 93.55 Cr
  • Profit Before Tax: Rs. 11.29 Cr, up 77.80% from Rs. 6.35 Cr
  • Profit After Tax: Rs. 8.31 Cr, up 79.87% from Rs. 4.62 Cr
  • Category-wise Sales Growth:
  • OTC Gross Sales: Rs. 96.79 Cr, up 20.19% from Rs. 80.53 Cr
  • Comfy Gross Sales: Rs. 30.59 Cr, up 10.75% from Rs. 27.62 Cr
  • Beverages Gross Sales: Rs. 9.69 Cr, down from Rs. 12.88 Cr (decline)
  • Electro Plus Sales: Rs. 8.70 Cr, down from Rs. 10.44 Cr (decline)
  • Volume Growth:
  • Pain Management head ache care segment back to double-digit volume growth; Head category volume growth 6.8% YoY; Body category volume growth 24.6% YoY.
  • Roll on category growing with market leadership; competition entry shows category attractiveness.
  • Outlook:
  • Focus on increasing operating profit margin (EBIT) from 11.44% to 13% by revenue growth and operational efficiency.

2 more points from Amrutanjan Health Care Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.

Amrutanjan Health Care Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Amrutanjan Health Care Ltd Q1 FY26 results — key figures

Amrutanjan Health Care Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue9484+11.9%135-30.4%
Operating profit (EBITDA)84+100%18-55.6%
Operating margin9%4.2%+4.8 pp13%-4 pp
Profit before tax116+83.3%21-47.6%
Net profit (PAT)85+60%15-46.7%
EPS (₹)2.871.60+79.4%5.25-45.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Amrutanjan Health Care Ltd Q1 FY26 results?

Overall Financial Performance Q1 FY26 vs Q1 FY25:. EBITDA/profit before tax (PBT) for Q1 FY26: Rs. 11.29 Cr, up 77.80% YoY (from Rs. 6.35 Cr in Q1 FY25) [Page 16].

What is Amrutanjan Health Care Ltd share price analysis?

Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.